Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 166 articles: HTML format

Single Articles

May 2025
1. WANG Y, Qiao S, Wang P, Li M, et al
   Copper's new role in cancer: how cuproptosis-related genes could revolutionize glioma treatment.
   BMC Cancer. 2025;25:859.
   PubMed     Abstract available
   
   
   
2. HAJIKARIMLOO B, Mohammadzadeh I, Tos SM, Habibi MA, et al
   Machine learning in prediction of epidermal growth factor receptor status in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:818.
   PubMed     Abstract available
   
   
   April 2025
3. WANG P, Wang J, Fang Z, Chen Q, et al
   Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy.
   BMC Cancer. 2025;25:815.
   PubMed     Abstract available
   
   
   
4. LIU J, Guan X, Gao S, Quan L, et al
   Novel insight of critical genes involved in breast cancer brain metastasis: evidence from a cross-tissue transcriptome association study and validation through external clinical cohorts.
   BMC Cancer. 2025;25:707.
   PubMed     Abstract available
   
   
   
5. CHUNG MW, Tzeng CC, Huang YC, Wei KC, et al
   Neutrophil-to-lymphocyte ratio dynamics: prognostic value and potential for surveilling glioblastoma recurrence.
   BMC Cancer. 2025;25:709.
   PubMed     Abstract available
   
   
   
6. ZHANG H, Wang Z, Qiao X, Wu J, et al
   Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study.
   BMC Cancer. 2025;25:654.
   PubMed     Abstract available
   
   
   
7. YIN X, Lin X, Zhang G, Yin Y, et al
   Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy.
   BMC Cancer. 2025;25:639.
   PubMed     Abstract available
   
   
   
8. WANG S, Guo J, Xian X, Li M, et al
   Correction: Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
   BMC Cancer. 2025;25:625.
   PubMed    
   
   
   
9. ZHENG J, Wang Z, Zhu H, Guo W, et al
   Impact of transducer arrays on deep-seated dosimetry in radiotherapy with concurrent TTFields for glioblastoma (extreme analysis).
   BMC Cancer. 2025;25:600.
   PubMed     Abstract available
   
   
   March 2025
10. WANG S, Guo J, Xian X, Li M, et al
    Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
    BMC Cancer. 2025;25:557.
    PubMed     Abstract available
    
    
    
11. CAO P, Jia X, Wang X, Fan L, et al
    Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.
    BMC Cancer. 2025;25:443.
    PubMed     Abstract available
    
    
    
12. MAWHINNEY G, Higham H, Leedham S, Ansorge O, et al
    Study protocol for putting the 'Person' in the PiCTuRE: an exploratory sequential mixed methods-based design, exploring how precision medicine is implemented and experienced by people living with a primary tumour of the craniospinal axis.
    BMC Cancer. 2025;25:420.
    PubMed     Abstract available
    
    
    
13. LIANG L, Lv W, Cheng G, Gao M, et al
    Impact of celastrol on mitochondrial dynamics and proliferation in glioblastoma.
    BMC Cancer. 2025;25:412.
    PubMed     Abstract available
    
    
    
14. INGGAS MAM, Patel U, Wijaya JH, Otinashvili N, et al
    The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:399.
    PubMed     Abstract available
    
    
    February 2025
15. SCHNEIDER M, Potthoff AL, Ahmadipour Y, Borger V, et al
    The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.
    BMC Cancer. 2025;25:306.
    PubMed     Abstract available
    
    
    
16. YANG X, Song Y, Xu R, Yang Y, et al
    Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study.
    BMC Cancer. 2025;25:266.
    PubMed     Abstract available
    
    
    
17. DEGUCHI S, Ohka F, Shiba Y, Yamaguchi J, et al
    Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma.
    BMC Cancer. 2025;25:251.
    PubMed     Abstract available
    
    
    
18. WU D, Huang Y, Wang B, Zheng Q, et al
    A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer.
    BMC Cancer. 2025;25:236.
    PubMed     Abstract available
    
    
    
19. ZHANG C, Lv Z, Liang H, Hu F, et al
    Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.
    BMC Cancer. 2025;25:226.
    PubMed     Abstract available
    
    
    
20. REZANEJAD-ASL P, Parhizkar Roudsari P, Rezaei N, Sharafkhah M, et al
    Pre-diagnostic risk factors for brain cancer incidence and survival: insights from the Golestan Cohort Study.
    BMC Cancer. 2025;25:210.
    PubMed     Abstract available
    
    
    January 2025
21. ZHOU Z, Liu J, Yue Q, Chen L, et al
    Optimal treatment approach for intracranial germinoma: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:26.
    PubMed     Abstract available
    
    
    December 2024
22. LESUEUR P, Clarisse B, Lequesne J, Licaj I, et al
    Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).
    BMC Cancer. 2024;24:1594.
    PubMed     Abstract available
    
    
    
23. POURSAEED R, Mohammadzadeh M, Safaei AA
    Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.
    BMC Cancer. 2024;24:1581.
    PubMed     Abstract available
    
    
    
24. DENG G, Zhang Q, Fan J, Zhao C, et al
    Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.
    BMC Cancer. 2024;24:1571.
    PubMed     Abstract available
    
    
    
25. ZHANG LY, Du HZ, Lu TT, Song SH, et al
    Long-term outcome of childhood and adolescent patients with craniopharyngiomas: a single center retrospective experience.
    BMC Cancer. 2024;24:1555.
    PubMed     Abstract available
    
    
    
26. PRADO MB, Coelho BP, Iglesia RP, Alves RN, et al
    Prion protein regulates invasiveness in glioblastoma stem cells.
    BMC Cancer. 2024;24:1539.
    PubMed     Abstract available
    
    
    
27. ZHANG X, Sun Q, Chen R, Zhao M, et al
    Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study.
    BMC Cancer. 2024;24:1492.
    PubMed     Abstract available
    
    
    
28. ROSSI J, Cavallieri F, Bassi MC, Venturelli F, et al
    To be or not to be: The dilemma over the prognostic role of epilepsy at presentation in patients with glioblastoma - a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1488.
    PubMed     Abstract available
    
    
    November 2024
29. HAJIKARIMLOO B, Habibi MA, Kooshki A, Alvani MS, et al
    Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1473.
    PubMed     Abstract available
    
    
    
30. DAVE B, Tailor J
    Human stem cell models to unravel brain cancer.
    BMC Cancer. 2024;24:1465.
    PubMed     Abstract available
    
    
    
31. LEE D, Lee E, Roh TH, Kim SH, et al
    Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.
    BMC Cancer. 2024;24:1450.
    PubMed     Abstract available
    
    
    
32. GU J, Huang X, Zhang Y, Bao C, et al
    Cerebrospinal fluid IL-6 and IL-10 as promising diagnostic and therapeutic prognostic biomarkers for secondary central nervous system lymphoma.
    BMC Cancer. 2024;24:1443.
    PubMed     Abstract available
    
    
    
33. HE Q, Wang W, Xu D, Xiong Y, et al
    Genetic association between mitochondrial DNA copy number and glioma risk: insights from causality.
    BMC Cancer. 2024;24:1439.
    PubMed     Abstract available
    
    
    October 2024
34. WANG T, Li R, Liu S, Wu Q, et al
    The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases.
    BMC Cancer. 2024;24:1343.
    PubMed     Abstract available
    
    
    
35. TONG Y, Wan X, Yin C, Lei T, et al
    In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.
    BMC Cancer. 2024;24:1305.
    PubMed     Abstract available
    
    
    
36. WANG Y, Xu H, Sa Q, Li L, et al
    Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.
    BMC Cancer. 2024;24:1262.
    PubMed     Abstract available
    
    
    
37. GAO L, Zhang R, Zhang W, Lan Y, et al
    Integrated bioinformatics analysis and experimental validation on malignant progression and immune cell infiltration of LTBP2 in gliomas.
    BMC Cancer. 2024;24:1252.
    PubMed     Abstract available
    
    
    September 2024
38. MOON HH, Park JE, Kim N, Kim YH, et al
    Prospective longitudinal analysis of imaging-based spatiotemporal tumor habitats in glioblastoma, IDH-wild type: implication in patient outcome using multiparametric physiologic MRI.
    BMC Cancer. 2024;24:1197.
    PubMed     Abstract available
    
    
    
39. RUSSO R, Verdolotti T, Perna A, Ruscelli L, et al
    Central nervous system pediatric multi-disciplinary tumor board: a single center experience.
    BMC Cancer. 2024;24:1146.
    PubMed     Abstract available
    
    
    
40. KHADHRAOUI E, Schmidt L, Klebingat S, Schwab R, et al
    Comparison of a new MR rapid wash-out map with MR perfusion in brain tumors.
    BMC Cancer. 2024;24:1139.
    PubMed     Abstract available
    
    
    
41. BAO H, Chen Y, Meng Z, Chu Z, et al
    The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis.
    BMC Cancer. 2024;24:1119.
    PubMed     Abstract available
    
    
    
42. AFSORDEH N, Pournajaf S, Bayat H, Mohajerani F, et al
    Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model.
    BMC Cancer. 2024;24:1099.
    PubMed     Abstract available
    
    
    August 2024
43. TIAN Y, Gao X, Yang X, Chen S, et al
    VEGFA contributes to tumor property of glioblastoma cells by promoting differentiation of myeloid-derived suppressor cells.
    BMC Cancer. 2024;24:1040.
    PubMed     Abstract available
    
    
    
44. HOSOYA K, Ozasa H, Tanji M, Yoshida H, et al
    Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.
    BMC Cancer. 2024;24:1030.
    PubMed     Abstract available
    
    
    
45. YAN J, Guo C, Zheng H, Li Y, et al
    Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.
    BMC Cancer. 2024;24:1022.
    PubMed     Abstract available
    
    
    
46. WEI R, Zhou J, Bui B, Liu X, et al
    Glioma actively orchestrate a self-advantageous extracellular matrix to promote recurrence and progression.
    BMC Cancer. 2024;24:974.
    PubMed     Abstract available
    
    
    
47. YU J, Fu J, Li Y, Hu G, et al
    Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: long-term results from a single-center experience.
    BMC Cancer. 2024;24:963.
    PubMed     Abstract available
    
    
    
48. YAO N, Qin Z, Chen M, Hu L, et al
    Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.
    BMC Cancer. 2024;24:953.
    PubMed     Abstract available
    
    
    
49. HIROSE T, Deguchi S, Yasui K, Inoue M, et al
    The indication of palliative whole-brain radiotherapy for patients with brain metastases: a simple prognostic scoring system in the era of stereotactic radiosurgery.
    BMC Cancer. 2024;24:940.
    PubMed     Abstract available
    
    
    
50. WANG J, Zheng Q, Wang Y, Wang C, et al
    Dosimetric comparison of ZAP-X, Gamma Knife, and CyberKnife stereotactic radiosurgery for single brain metastasis.
    BMC Cancer. 2024;24:936.
    PubMed     Abstract available
    
    
    July 2024
51. ZOTO MUSTAFAYEV T, Turna M, Bolukbasi Y, Tezcanli E, et al
    Clinical and radiological effects of Bevacizumab for the treatment of radionecrosis after stereotactic brain radiotherapy.
    BMC Cancer. 2024;24:918.
    PubMed     Abstract available
    
    
    
52. LI Z, Wang J, Deng L, Zhai Y, et al
    Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost in lung cancer brain metastases and utility of the Hopkins verbal learning test for testing cognitive impairment in Chinese patients: a prospective phase II study.
    BMC Cancer. 2024;24:899.
    PubMed     Abstract available
    
    
    
53. DUAN Y, Wang Y, Zhang X, Huang J, et al
    Prevalence of dysphagia following posterior fossa tumor resection: a systematic review and meta?analysis.
    BMC Cancer. 2024;24:896.
    PubMed     Abstract available
    
    
    
54. BICKERDIKE MJ, Nafia I, Bessede A, Chen CB, et al
    AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.
    BMC Cancer. 2024;24:889.
    PubMed     Abstract available
    
    
    
55. ROH YH, Park JE, Park SY, Cho YH, et al
    Assessment of imaging risks for recurrence after stereotactic radiosurgery for brain metastases (IRRaS-BM).
    BMC Cancer. 2024;24:866.
    PubMed     Abstract available
    
    
    
56. LI X, Zhang Y, Ye Y, Tian S, et al
    Carbon-ion radiotherapy alone vs. standard dose photon radiation with carbon-ion radiotherapy boost for high-grade gliomas: a retrospective study.
    BMC Cancer. 2024;24:837.
    PubMed     Abstract available
    
    
    
57. CHANG T, Zhang R, Gan J, Yang Y, et al
    Investigating distinct clinical features and constructing a nomogram model for survival probability in adults with cerebellar high-grade gliomas.
    BMC Cancer. 2024;24:836.
    PubMed     Abstract available
    
    
    
58. LI YA, Zhao C, Ge JJ, Li C, et al
    Correction: Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.
    BMC Cancer. 2024;24:829.
    PubMed    
    
    
    
59. XIE X, Luo C, Wu S, Qiao W, et al
    Recursive partitioning analysis for survival stratification and early imaging prediction of molecular biomarker in glioma patients.
    BMC Cancer. 2024;24:818.
    PubMed     Abstract available
    
    
    
60. SU Y, Cheng R, Guo J, Zhang M, et al
    Differentiation of glioma and solitary brain metastasis: a multi-parameter magnetic resonance imaging study using histogram analysis.
    BMC Cancer. 2024;24:805.
    PubMed     Abstract available
    
    
    
61. XIAO Y, Wu W, Liu F, Jia Y, et al
    The clinical significance of inflammatory mediators in predicting obesity and progression-free survival in patients with adult-onset Craniopharyngioma.
    BMC Cancer. 2024;24:799.
    PubMed     Abstract available
    
    
    June 2024
62. LI YA, Zhao C, Ge JJ, Li C, et al
    Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.
    BMC Cancer. 2024;24:754.
    PubMed     Abstract available
    
    
    
63. LAKOMY R, Lojova M, Souckova L, Hynkova L, et al
    (11)C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET).
    BMC Cancer. 2024;24:736.
    PubMed     Abstract available
    
    
    
64. LIU ZY, Tang F, Wang J, Yang JZ, et al
    Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study.
    BMC Cancer. 2024;24:692.
    PubMed     Abstract available
    
    
    May 2024
65. ZHANG LY, Guo W, Du HZ, Pan H, et al
    Brachytherapy in craniopharyngiomas: a systematic review and meta-analysis of long-term follow-up.
    BMC Cancer. 2024;24:637.
    PubMed     Abstract available
    
    
    
66. AZIMI P, Yazdanian T, Ahmadiani A
    mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
    BMC Cancer. 2024;24:612.
    PubMed     Abstract available
    
    
    
67. WANG J, Wang G, Cheng L, Zhu H, et al
    Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
    BMC Cancer. 2024;24:572.
    PubMed     Abstract available
    
    
    April 2024
68. KUMTHEKAR P, Lyleroehr M, Lacson L, Lukas RV, et al
    A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
    BMC Cancer. 2024;24:527.
    PubMed     Abstract available
    
    
    
69. LIU C, Liu F, Nie D, Xiao Y, et al
    Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma.
    BMC Cancer. 2024;24:521.
    PubMed     Abstract available
    
    
    
70. DVORAKOVA K, Skarkova V, Vitovcova B, Soukup J, et al
    Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
    BMC Cancer. 2024;24:509.
    PubMed     Abstract available
    
    
    
71. SHI MX, Ding X, Tang L, Cao WJ, et al
    PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
    BMC Cancer. 2024;24:504.
    PubMed     Abstract available
    
    
    
72. ORESKOVIC D, Madero Pohlen A, Cvitkovic I, Alen JF, et al
    Chronic hyperglycemia and intracranial meningiomas.
    BMC Cancer. 2024;24:488.
    PubMed     Abstract available
    
    
    
73. DENG MY, da Silva AS, Goller PC, Konig L, et al
    Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07).
    BMC Cancer. 2024;24:449.
    PubMed     Abstract available
    
    
    
74. KONG C, Yin X, Zou J, Ma C, et al
    The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
    BMC Cancer. 2024;24:454.
    PubMed     Abstract available
    
    
    
75. CHEN M, Li R, Kong Y, Shi L, et al
    Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
    BMC Cancer. 2024;24:429.
    PubMed     Abstract available
    
    
    March 2024
76. WANG G, Ren X, Li J, Cui R, et al
    High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.
    BMC Cancer. 2024;24:385.
    PubMed     Abstract available
    
    
    
77. ZHANG W, Blank A, Kremenetskaia I, Nitzsche A, et al
    CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.
    BMC Cancer. 2024;24:369.
    PubMed     Abstract available
    
    
    
78. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    PubMed     Abstract available
    
    
    
79. MA Y, Gong Y, Qiu Q, Ma C, et al
    Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.
    BMC Cancer. 2024;24:363.
    PubMed     Abstract available
    
    
    
80. HUANG Y, Wu Z, Peng Z, Liu A, et al
    Hsa_circ_0004872 alleviates meningioma progression by sponging miR-190a-3p/PTEN signaling.
    BMC Cancer. 2024;24:345.
    PubMed     Abstract available
    
    
    
81. ROUTMAN DM, Jusue-Torres I, Brown PD, Trifiletti DM, et al
    Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial.
    BMC Cancer. 2024;24:332.
    PubMed     Abstract available
    
    
    
82. MENG J, Qian W, Yang Z, Gong L, et al
    p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    BMC Cancer. 2024;24:317.
    PubMed     Abstract available
    
    
    February 2024
83. SUN L, Jin X, Xie L, Xu G, et al
    Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2024;24:275.
    PubMed    
    
    
    
84. QIAO W, Wang Y, Luo C, Wu J, et al
    Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study.
    BMC Cancer. 2024;24:274.
    PubMed     Abstract available
    
    
    
85. KINO S, Kanamori M, Shimoda Y, Niizuma K, et al
    Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.
    BMC Cancer. 2024;24:222.
    PubMed     Abstract available
    
    
    
86. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
    Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    BMC Cancer. 2024;24:219.
    PubMed     Abstract available
    
    
    
87. LI G, Ma L, Feng C, Yin H, et al
    MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
    BMC Cancer. 2024;24:220.
    PubMed     Abstract available
    
    
    
88. BOCCACINO JM, Dos Santos Peixoto R, Fernandes CFL, Cangiano G, et al
    Integrated transcriptomics uncovers an enhanced association between the prion protein gene expression and vesicle dynamics signatures in glioblastomas.
    BMC Cancer. 2024;24:199.
    PubMed     Abstract available
    
    
    
89. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    PubMed     Abstract available
    
    
    
90. PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
    A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    BMC Cancer. 2024;24:176.
    PubMed     Abstract available
    
    
    
91. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    PubMed     Abstract available
    
    
    January 2024
92. ZHANG X, Li Y, Zhang G, Ma C, et al
    Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004-2020.
    BMC Cancer. 2024;24:154.
    PubMed     Abstract available
    
    
    
93. VAN TILBURG CM, Kilburn LB, Perreault S, Schmidt R, et al
    LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    BMC Cancer. 2024;24:147.
    PubMed     Abstract available
    
    
    
94. YU W, Zhou M, Niu H, Li J, et al
    Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
    BMC Cancer. 2024;24:140.
    PubMed     Abstract available
    
    
    
95. YAO B, Wang H, Wu X, Wang C, et al
    A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics.
    BMC Cancer. 2024;24:138.
    PubMed     Abstract available
    
    
    
96. HEUER S, Burghaus I, Gose M, Kessler T, et al
    PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
    BMC Cancer. 2024;24:135.
    PubMed     Abstract available
    
    
    
97. LU Y, Liao L, Du K, Mo J, et al
    Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
    BMC Cancer. 2024;24:133.
    PubMed     Abstract available
    
    
    
98. LIU JS, Cai YX, He YZ, Xu J, et al
    Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    BMC Cancer. 2024;24:123.
    PubMed     Abstract available
    
    
    
99. QIAN J, He Z, Wu Y, Li H, et al
    Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    BMC Cancer. 2024;24:117.
    PubMed     Abstract available
    
    
    
100. YANG W, Han Y, He C, Zhong S, et al
     Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis.
     BMC Cancer. 2024;24:118.
     PubMed     Abstract available
     
     
     
101. ZHU X, Liu Y, Guo W, Liang Q, et al
     Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review.
     BMC Cancer. 2024;24:110.
     PubMed     Abstract available
     
     
     
102. LI L, Xia S, Zhao Z, Deng L, et al
     EMP3 as a prognostic biomarker correlates with EMT in GBM.
     BMC Cancer. 2024;24:89.
     PubMed     Abstract available
     
     
     
103. ZUCHEGNA C, Leone S, Romano A, Porcellini A, et al
     KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
     BMC Cancer. 2024;24:77.
     PubMed     Abstract available
     
     
     
104. MASTALL M, Roth P, Bink A, Fischer Maranta A, et al
     A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
     BMC Cancer. 2024;24:82.
     PubMed     Abstract available
     
     
     
105. BHASKARAN D, Savage J, Patel A, Collinson F, et al
     A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
     BMC Cancer. 2024;24:83.
     PubMed     Abstract available
     
     
     
106. HUANG CY, Bai MH, Shen JW, Sun QQ, et al
     Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
     BMC Cancer. 2024;24:57.
     PubMed     Abstract available
     
     
     
107. SUN Y, Liu P, Wang Z, Zhang H, et al
     Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma.
     BMC Cancer. 2024;24:37.
     PubMed     Abstract available
     
     
     
108. CRUCITTA S, Pasqualetti F, Gonnelli A, Ruglioni M, et al
     IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
     BMC Cancer. 2024;24:31.
     PubMed     Abstract available
     
     
     
109. MOHAJERANI F, Tehrankhah ZM, Rahmani S, Afsordeh N, et al
     CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-kappaB signaling pathway in glioblastoma multiforme.
     BMC Cancer. 2024;24:19.
     PubMed     Abstract available
     
     
     
110. OUDIN A, Moreno-Sanchez PM, Baus V, Niclou SP, et al
     Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
     BMC Cancer. 2024;24:3.
     PubMed     Abstract available
     
     
     
111. ZHAO S, Zhang M, Zhang Q, Wu J, et al
     Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
     BMC Cancer. 2024;24:6.
     PubMed     Abstract available
     
     
     December 2023
112. DAI L, Zhou P, Lyu L, Jiang S, et al
     Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
     BMC Cancer. 2023;23:1249.
     PubMed     Abstract available
     
     
     
113. ZHANG K, Zhang T, Guo Z, Zhao F, et al
     Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
     BMC Cancer. 2023;23:1240.
     PubMed     Abstract available
     
     
     
114. ADEGBOYEGA B, Joseph A, Alabi A, Omomila J, et al
     Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center.
     BMC Cancer. 2023;23:1233.
     PubMed     Abstract available
     
     
     
115. BAI J, He M, Gao E, Yang G, et al
     Radiomic texture analysis based on neurite orientation dispersion and density imaging to differentiate glioblastoma from solitary brain metastasis.
     BMC Cancer. 2023;23:1231.
     PubMed     Abstract available
     
     
     November 2023
116. SENRUNG A, Tripathi T, Yadav J, Janjua D, et al
     In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.
     BMC Cancer. 2023;23:1173.
     PubMed     Abstract available
     
     
     
117. ZHANG Y, Wu X, Zhu J, Lu R, et al
     Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression.
     BMC Cancer. 2023;23:1120.
     PubMed     Abstract available
     
     
     October 2023
118. SONG Y, Lin S, Chen J, Dang J, et al
     First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:1043.
     PubMed     Abstract available
     
     
     
119. WEI D, Niu B, Zhai B, Liu XB, et al
     Expression profiles and function prediction of tRNA-derived fragments in glioma.
     BMC Cancer. 2023;23:1015.
     PubMed     Abstract available
     
     
     
120. YANG XS, Zhu P, Xie RX, Chen PF, et al
     Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image.
     BMC Cancer. 2023;23:1012.
     PubMed     Abstract available
     
     
     
121. ROZATI H, Chen J, Williams M
     Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:1004.
     PubMed     Abstract available
     
     
     
122. WANG Z, Cui Y, Wang F, Xu L, et al
     DNA methylation-regulated LINC02587 inhibits ferroptosis and promotes the progression of glioma cells through the CoQ-FSP1 pathway.
     BMC Cancer. 2023;23:989.
     PubMed     Abstract available
     
     
     
123. VINCENT CA, Nissen I, Dakhel S, Hornblad A, et al
     Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
     BMC Cancer. 2023;23:945.
     PubMed     Abstract available
     
     
     
124. ROBINSON SD, Samuels M, Jones W, Gilbert D, et al
     Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
     BMC Cancer. 2023;23:939.
     PubMed     Abstract available
     
     
     
125. MING Y, Luo C, Ji B, Cheng J, et al
     ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
     BMC Cancer. 2023;23:937.
     PubMed     Abstract available
     
     
     September 2023
126. CHENG WY, Shen CC, Liang YJ, Chiao MT, et al
     Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
     BMC Cancer. 2023;23:886.
     PubMed     Abstract available
     
     
     
127. HATTORI EY, Arakawa Y, Mineharu Y, Furukawa K, et al
     Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
     BMC Cancer. 2023;23:849.
     PubMed     Abstract available
     
     
     
128. SHAN E, Cao YN, Zhang Y, Chen W, et al
     Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
     BMC Cancer. 2023;23:846.
     PubMed     Abstract available
     
     
     
129. LIU Z, Hong X, Wang L, Ma Z, et al
     Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas.
     BMC Cancer. 2023;23:848.
     PubMed     Abstract available
     
     
     August 2023
130. MIRANDA J, Vazquez-Blomquist D, Bringas R, Fernandez-de-Cossio J, et al
     A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
     BMC Cancer. 2023;23:806.
     PubMed     Abstract available
     
     
     
131. TAN C, Wei J, Li Z, Tian N, et al
     Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma.
     BMC Cancer. 2023;23:808.
     PubMed     Abstract available
     
     
     
132. WANG X, Chen J, Lei Z, Chen H, et al
     Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus‑avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple i
     BMC Cancer. 2023;23:796.
     PubMed     Abstract available
     
     
     
133. NEUTEL CLG, Viozzi I, Overduin CG, Rijpma A, et al
     Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
     BMC Cancer. 2023;23:788.
     PubMed     Abstract available
     
     
     
134. SOUSA N, Geiss C, Bindila L, Lieberwirth I, et al
     Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
     BMC Cancer. 2023;23:762.
     PubMed     Abstract available
     
     
     
135. ZHAO N, Weng S, Liu Z, Xu H, et al
     CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
     BMC Cancer. 2023;23:749.
     PubMed     Abstract available
     
     
     
136. ZHONG K, Shi Y, Gao Y, Zhang H, et al
     First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
     BMC Cancer. 2023;23:746.
     PubMed     Abstract available
     
     
     
137. LI J, Guo Q, Xing R
     Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
     BMC Cancer. 2023;23:727.
     PubMed     Abstract available
     
     
     July 2023
138. TAN Q, Wang Q, Jin S, Zhou F, et al
     Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers.
     BMC Cancer. 2023;23:712.
     PubMed     Abstract available
     
     
     
139. CHIEN CH, Lai CC, Chuang JY, Chu JM, et al
     Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
     BMC Cancer. 2023;23:713.
     PubMed     Abstract available
     
     
     
140. WALTENBERGER M, Bernhardt D, Diehl C, Gempt J, et al
     Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
     BMC Cancer. 2023;23:709.
     PubMed     Abstract available
     
     
     
141. TAO R, Huang R, Yang J, Wang J, et al
     Comprehensive analysis of the clinical and biological significances of cholesterol metabolism in lower-grade gliomas.
     BMC Cancer. 2023;23:692.
     PubMed     Abstract available
     
     
     
142. YUEYANG M, Yaqin H, Guolian X, Wenjian Z, et al
     Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text]/VEGF-A signaling axis.
     BMC Cancer. 2023;23:662.
     PubMed     Abstract available
     
     
     June 2023
143. PENG Y, Liu H, Wu Q, Wang L, et al
     Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
     BMC Cancer. 2023;23:596.
     PubMed     Abstract available
     
     
     
144. XUE Z, Wang J, Wang Z, Liu J, et al
     SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
     BMC Cancer. 2023;23:589.
     PubMed     Abstract available
     
     
     
145. SUN S, Yang C, Wang K, Huang R, et al
     Molecular and clinical characterization of PTRF in glioma via 1,022 samples.
     BMC Cancer. 2023;23:551.
     PubMed     Abstract available
     
     
     
146. WEI L, Pan M, Jiang Q, Hu B, et al
     Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway.
     BMC Cancer. 2023;23:550.
     PubMed     Abstract available
     
     
     
147. FU M, Zhou Z, Huang X, Chen Z, et al
     Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
     BMC Cancer. 2023;23:544.
     PubMed     Abstract available
     
     
     
148. HAO Z, Huajun S, Zhen G, Yu X, et al
     AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
     BMC Cancer. 2023;23:516.
     PubMed     Abstract available
     
     
     
149. BABAZADEH SM, Zolfaghari MR, Zargar M, Baesi K, et al
     Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.
     BMC Cancer. 2023;23:519.
     PubMed     Abstract available
     
     
     May 2023
150. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
     Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
     BMC Cancer. 2023;23:468.
     PubMed     Abstract available
     
     
     
151. CHEN Y, Ma F, Zhang Z, Guo Y, et al
     LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
     BMC Cancer. 2023;23:455.
     PubMed     Abstract available
     
     
     
152. DUAN X, Yang B, Zhao C, Tie B, et al
     Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
     BMC Cancer. 2023;23:432.
     PubMed     Abstract available
     
     
     
153. LIU ZY, Lan T, Tang F, He YZ, et al
     ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
     BMC Cancer. 2023;23:420.
     PubMed     Abstract available
     
     
     
154. WANG X, Zhang H, Zhang M, Zhang X, et al
     Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
     BMC Cancer. 2023;23:415.
     PubMed     Abstract available
     
     
     
155. ZOU R, Zhong X, Liang K, Zhi C, et al
     Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
     BMC Cancer. 2023;23:403.
     PubMed     Abstract available
     
     
     April 2023
156. THIVAT E, Casile M, Moreau J, Molnar I, et al
     Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
     BMC Cancer. 2023;23:344.
     PubMed     Abstract available
     
     
     
157. ZHOU T, Zhu S, Xiong Q, Gan J, et al
     Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
     BMC Cancer. 2023;23:333.
     PubMed     Abstract available
     
     
     
158. KELLER KM, Koetsier J, Schild L, Amo-Addae V, et al
     The potential of PARP as a therapeutic target across pediatric solid malignancies.
     BMC Cancer. 2023;23:310.
     PubMed     Abstract available
     
     
     March 2023
159. WANG H, Xing R, Li M, Zhang M, et al
     Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
     BMC Cancer. 2023;23:289.
     PubMed     Abstract available
     
     
     
160. CROUZEN JA, Petoukhova AL, Broekman MLD, Fiocco M, et al
     SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
     BMC Cancer. 2023;23:273.
     PubMed     Abstract available
     
     
     
161. KING AL, Acquaye-Mallory AA, Vera E, Mendoza T, et al
     Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
     BMC Cancer. 2023;23:262.
     PubMed     Abstract available
     
     
     
162. LIU X, Li Z, Sun J, Zhang Z, et al
     Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
     BMC Cancer. 2023;23:259.
     PubMed     Abstract available
     
     
     
163. ZHANG M, Liu X, Wang D, Ruan X, et al
     A novel cuproptosis-related gene signature to predict prognosis in Glioma.
     BMC Cancer. 2023;23:237.
     PubMed     Abstract available
     
     
     
164. CAIN SA, Pope B, Mangiola S, Mantamadiotis T, et al
     Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
     BMC Cancer. 2023;23:216.
     PubMed     Abstract available
     
     
     
165. XU Z, Hao X, Wang Q, Yang K, et al
     Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
     BMC Cancer. 2023;23:206.
     PubMed     Abstract available
     
     
     
166. GEURTS BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, et al
     Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
     BMC Cancer. 2023;23:205.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.